Biomedical interventions for HIV prevention in MSM in Amsterdam: a demonstration project

Phase 4

Completed

• Conditions: pre-exposure prophylaxis; Prevention of HIV infection with medication; 10047438

• Registration Number: NL-OMON42253
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 370

Inclusion Criteria

see below

Exclusion Criteria

One of the following:1. Signs or symptoms of acute HIV infection2. Hepatitis B
infection (i.e. HbsAg positive)3. Unlikely, in the opinion of the clinician, to
comply with project schedule4. Hypersensitivity for one of the components of
fixed combination tablet containing tenofovir and emtricitabine5. Creatinine
clearing using cockroft gault formula: < 60 ml/minrolegroepContr

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To study acceptability, feasibility and uptake of PrEP</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secundary endpoints are: medication adherence, side effects, incidence of hiv<br /><br>and viral resistance in case of incident HIV infection, changes in risk<br /><br>behaviour and changes in STI prevalence.</p><br>